Affiliation:
1. St. James’s Hospital, LS9 7TF Dublin, Ireland
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune multisystem inflammatory disease in which lung involvement is the most common extra-articular manifestation. Parenchymal lung involvement or interstitial lung disease (ILD) is a significant cause of morbidity and mortality and there is a paucity of evidence-based guidance on how to best treat RA-ILD. This review article aims to evaluate the evidence from cohort studies and best real word data from registries. Extensive discussion of the relative merits and drawbacks of glucocorticoids, various biologics, small molecules and anti-fibrotics is presented. The limited available guidelines in RA-ILD are also discussed and a rational treatment algorithm is offered.
Reference68 articles.
1. Rheumatoid Arthritis;Smolen;Lancet,2016
2. Cause of death in autopsied RA patients;Toyoshima;Ryumachi,1993
3. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study;Bongartz;Arthritis Rheum.,2010
4. Management of connective tissue diseases associated interstitial lung disease: A review of the published literature;Wallace;Curr. Opin. Rheumatol.,2016
5. Kiely, P., Busby, A.D., Nikiphorou, E., Sullivan, K., A Walsh, D., Creamer, P., Dixey, J., and Young, A. (2019). Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. BMJ Open, 9.